A recombinant collagen-based ointment-type biological dressing for wound repair, its preparation method and application.

By combining O-sulfonated carboxymethyl chitosan with recombinant collagen, a dressing with a structure mimicking heparan sulfate was constructed. This solved the problems of low utilization of endogenous growth factors and anticoagulant side effects in wound dressings, achieving growth factor stability and protecting collagen activity, thus promoting wound healing.

CN123101733APending Publication Date: 2026-11-17XINJIANG AIYOUHE BIOPHARMACEUTICAL CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611572251.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-12
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing wound dressings cannot effectively utilize endogenous growth factors in wound exudate. The growth factor binding function and anticoagulant side effects of sulfonated polysaccharide materials cannot be decoupled, and recombinant collagen is easily inactivated at emulsification high temperatures.

Method used

An ointment-type biological dressing composed of O-sulfonated carboxymethyl chitosan and recombinant collagen is used. Through sulfonation, a glycosaminoglycan structure mimicking heparan sulfate is constructed on the molecular chain to bind and stabilize endogenous growth factors, avoiding anticoagulant activity. A decreasing temperature gradient emulsification process is used to protect collagen activity.

Benefits of technology

It achieves in-situ capture and stabilization of endogenous growth factors, prolongs the half-life of growth factors, avoids anticoagulation side effects, maintains the bioactivity of collagen, and meets the needs of biosafety and healing promotion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123101733A_ABST
    Figure CN123101733A_ABST
Patent Text Reader

Abstract

This invention discloses a recombinant collagen-based ointment-type biological dressing for wound repair, its preparation method, and its application, belonging to the field of biomedical materials technology. The dressing contains, by weight percentage, 0.5-2.0 wt% O-sulfonated carboxymethyl chitosan, 0.2-1.0 wt% recombinant collagen, with the remainder being excipient matrix and purified water. The O-sulfonated carboxymethyl chitosan is obtained through sulfonation and solvent extraction of N-sulfate from aqueous dimethyl sulfoxide. The sulfonic acid groups are linked to the hydroxyl oxygen of the sugar ring via sulfate bonds, retaining free amino groups. This allows it to capture and stabilize endogenous growth factors such as FGF-2 and VEGF165 in wound exudate in situ, exhibiting anticoagulant activity far lower than heparin, thus decoupling growth factor capture from anticoagulant side effects. The preparation employs a decreasing temperature gradient emulsification process, with recombinant collagen added at 30-35℃ to maintain the integrity of its triple helix structure. This dressing is used to prepare medical dressings that promote wound healing.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical materials technology, specifically to a recombinant collagen-based ointment-type biological dressing for wound repair, its preparation method, and its application. Background Technology

[0002] Wound dressings are medical materials used to cover wounds and provide a suitable healing microenvironment. Compared with traditional gauze dressings, ointment-type dressings can be applied directly to the wound surface, forming a protective film and providing physical isolation, thus creating a moist healing microenvironment. They are widely used in the care of superficial wounds, mechanical trauma, wounds after laser or photon therapy, and other non-chronic wounds and surrounding skin. Recombinant collagen has low immunogenicity and good cell compatibility; its introduction into ointment-type dressings can further support the wound repair process. Chinese patent application CN121313520A discloses an ointment containing bioactive ingredients and its preparation process, in which the material temperature is lowered to 40-50°C after the emulsification process before adding the bioactive ingredients to reduce the impact of high temperature on activity. However, this type of process only empirically controls the addition temperature. The emulsification stage is still at a high temperature above 75°C. Heat-sensitive biomolecules such as collagen are still prone to irreversible denaturation and aggregation during the mixing and cooling process. The activity lacks a systematic temperature gradient protection design. More importantly, it does not involve how to utilize the endogenous growth factors already present in the wound exudate.

[0003] Wound exudate contains endogenous growth factors such as fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), which are key signaling molecules driving granulation tissue formation and re-epithelialization. However, the concentrations of matrix metalloproteinases and serine proteases in the wound microenvironment are significantly higher than in normal tissue. Free endogenous growth factors are rapidly degraded and inactivated under protease attack, with a half-life typically less than 1 hour, creating a dilemma where growth factors are present but ineffective. In 2012, Volpato et al. reported that heparin-mimicking sulfonated polysaccharides could stabilize FGF-2 in vitro and maintain its biological activity; Paluck et al. systematically reviewed strategies for heparin-mimicking polymers to present growth factors in 2016. However, these studies have remained at the solution system and cell biology level, failing to develop dressing formulations that can be applied to wounds and produced on a large scale, and also failing to address the biosafety issues of the sulfonated materials themselves.

[0004] The synthetic chemistry of sulfonated polysaccharides has been reported. Chinese Patent CN104231112B discloses a 6-O-carboxymethyl chitosan sulfate and its preparation method, which imparts a heparin-like structure to the material through sulfonation for anticoagulant purposes. In this technical route, the sulfonation operation is geared towards achieving high anticoagulant activity. However, anticoagulant activity poses an undesirable systemic risk for topical wound dressings: sulfonated polysaccharides absorbed through the wound may interfere with the body's coagulation function; simultaneously, high-intensity sulfonation consumes free amino groups on the chitosan molecular chain, weakening its antibacterial and film-forming properties. Those skilled in the art, when faced with the material selection issue for wound dressings, have no incentive to introduce highly sulfonated chitosan, which is generally recognized in the art for its anticoagulant applications, into wound dressings.

[0005] In summary, existing technologies have significant shortcomings in the following aspects: First, wound dressings cannot capture and stabilize endogenous growth factors in wound exudate in situ, resulting in low utilization rates of endogenous growth factors; second, the growth factor binding function and anticoagulant side effects of sulfonated polysaccharide materials cannot be decoupled, making it difficult to meet the biosafety requirements of topical dressings; and third, the emulsification process of ointment-type dressings lacks a systematic activity protection design for heat-sensitive active components such as collagen. Therefore, there is an urgent need for a novel biological dressing for wound repair that can simultaneously address the above problems. Summary of the Invention

[0006] The purpose of this invention is to provide a recombinant collagen-based ointment-type biological dressing for wound repair, its preparation method, and its application, in order to solve the problems of existing wound dressings being unable to effectively utilize endogenous growth factors in wound exudate, the inability to decouple the growth factor binding function and anticoagulant side effects of sulfonated polysaccharide materials, and the easy inactivation of recombinant collagen under emulsification high temperature.

[0007] To solve the above-mentioned technical problems, the present invention provides the following technical solution: In a first aspect, the present invention provides a recombinant collagen-based ointment-type biological dressing for wound repair. The biological dressing is an ointment made from active ingredients, excipient matrix, and purified water; the active ingredients include O-sulfonated carboxymethyl chitosan and recombinant collagen.

[0008] The O-sulfonated carboxymethyl chitosan is prepared by sulfonation of carboxymethyl chitosan and a sulfur trioxide pyridine complex. The sulfonic acid group is linked to the hydroxyl oxygen atom of the pyranose ring of the carboxymethyl chitosan via a sulfate ester bond, while the amino group is retained, resulting in a carboxymethyl chitosan derivative. Unlike existing high-strength sulfonated chitosans designed for anticoagulation, the O-sulfonated carboxymethyl chitosan of this invention introduces sulfonic acid groups through sulfonation and then removes N-sulfate ester byproducts via selective solvent extraction. This constructs a sulfonic acid group array on the molecular chain that mimics the glycosaminoglycan structure of heparan sulfate, while retaining free amino groups. This allows for the specific binding and stabilization of endogenous growth factors in wound exudate, with anticoagulant activity far lower than heparin, thus decoupling the growth factor binding function from the anticoagulant side effects. The retention of free amino groups also preserves the material's antibacterial and film-forming properties. Compared with existing routes that use metal ions as temporary protecting groups to achieve O-position selective sulfonation, this invention does not use any protecting groups, thus avoiding the risk of unwanted metal ion residues in medical products, and the process is simpler.

[0009] Furthermore, by mass percentage, the content of O-sulfonated carboxymethyl chitosan in the biological dressing is 0.5~2.0 wt%, the content of recombinant collagen is 0.2~1.0 wt%, and the balance is excipient matrix and purified water.

[0010] Further, by weight percentage, the excipient matrix comprises: 5-7 wt% cetearyl alcohol, 7-9 wt% liquid paraffin, 3-5 wt% dimethicone, 2-3 wt% polysorbate 80, 7-9 wt% glycerin, 0.3-0.5 wt% carbomer, 0.1-0.3 wt% xanthan gum, 0.4-0.8 wt% triethanolamine, 0.1-0.2 wt% methylparaben, 0.04-0.08 wt% propylparaben, and 0.03-0.06 wt% disodium edetate.

[0011] Secondly, the present invention provides a method for preparing the above-mentioned recombinant collagen-based ointment-type biological dressing for wound repair, comprising intermediate preparation and dressing preparation, specifically including the following steps: S1. Swelling: Carboxymethyl chitosan is dispersed in N,N-dimethylformamide and swelled for 10-14 hours to allow the solvent to fully penetrate into the molecular chain; S2, sulfonation: Sulfur trioxide pyridine complex is added in batches and reacted with carboxymethyl chitosan. The sulfonic acid group is attached to the hydroxyl oxygen and amino nitrogen of the sugar ring to obtain N,O- mixed sulfonated products. S3. Alcohol precipitation purification: Pour the reaction solution into 4 times the volume of anhydrous ethanol, centrifuge to collect the precipitate, redissolve the precipitate in purified water to remove N,N-dimethylformamide and pyridine, and obtain the redissolved solution. S4, De-sulfonation: The complex solution is mixed with dimethyl sulfoxide and solvoly dissolved in an aqueous dimethyl sulfoxide system to selectively remove N-sulfate bonds. N-sulfate bonds are easily dissolved in an aqueous dimethyl sulfoxide system, while O-sulfate bonds remain stable under these conditions. Therefore, solvolysis can selectively remove N-sulfate bonds generated by side reactions, restore free amino groups, and retain the sulfonic acid group on the hydroxyl oxygen atom of the sugar ring, thereby achieving N-amino retention. S5. Dialysis Desalination and Freeze-drying: Dialyze for 72 hours using a dialysis bag with a molecular weight cutoff of 3.5 kDa, changing the water 6-8 times until the conductivity of the dialysate is less than 10 μS / cm; adjust the pH of the solution to 6.5-7.0 with a 0.1 mol / L sodium hydroxide aqueous solution to convert the sulfonic acid group to the sodium form; then pre-freeze at -50℃ for 4 hours, and freeze-dry under vacuum at 10-20 Pa for 48 hours to obtain the sodium form O-sulfonated carboxymethyl chitosan intermediate (its 1% aqueous solution has a pH of 6.5-7.0), and discharge after quality inspection; S6. Preparation of aqueous phase: Purified water, glycerol, pre-swollen carbomer, xanthan gum, disodium edetate, methylparaben and propylparaben are added to an emulsifying pot, heated to 75°C and stirred until homogeneous to obtain the aqueous phase; S7. Preparation of oil phase: Cetearyl alcohol, liquid paraffin, dimethyl silicone oil and polysorbate 80 are mixed in an oil phase pot, heated to melt, and heated to 78°C to obtain the oil phase; S8. Vacuum homogenization emulsification: The oil phase is drawn into the emulsification pot through a vacuum and homogenized and emulsified under vacuum conditions. S9, Neutralization and Thickening: Cool down the jacket, add triethanolamine, stir for 10 minutes, and thicken with carbomer. S10. Intermediate Dispersion: Continue cooling, add O-sulfonated carboxymethyl chitosan intermediate pre-dissolved in 10 times its mass of purified water, and disperse evenly with a frame-type stirring paddle at a low speed of 60~100 r / min for 20~40 min. At this temperature, the sulfonic acid groups and amino zwitterions are fully hydrated and extended, which is conducive to the full interpenetration between the intermediate and the aqueous phase. The pre-solution of the intermediate is weakly neutral (pH 6.5~7.0), which matches the pH of the carbomer system neutralized and thickened by triethanolamine, and its addition will not disturb the thickening state of the system. After dispersion, samples are taken at the top, middle and bottom of the emulsifying pot to determine the content of O-sulfonated carboxymethyl chitosan. The dispersion is considered to be uniform if the relative standard deviation of the content at the three points does not exceed 5%. S11. Collagen Addition, Defoaming, and Filling: Continue cooling, add the recombinant collagen aqueous solution, and stir at a low speed of 40-60 r / min for 15-30 min until homogeneous. Recombinant collagen will undergo irreversible denaturation and aggregation at emulsification temperatures above 75℃. Limiting its addition temperature to the range of 30-35℃ is key to maintaining its bioactivity (experiments show that when added within the range of 30-35℃, the retention rate of the triple helix structure of recombinant collagen in the finished product is 90%-95%; when added within the range of 40-50℃, it drops to 55%-65%). Then maintain slow stirring at 20-30 r / min, vacuum to -0.09 MPa for defoaming for 10-15 min, discharge the material, and fill it through the filling and capping line to obtain the final product.

[0012] Furthermore, in step S1, the swelling temperature is 4~10℃.

[0013] Further, in step S2, the molar ratio of the sugar units of carboxymethyl chitosan to the sulfur trioxide pyridine complex is 1:(1.5~3.0), the sulfonation reaction temperature is 20~45℃, and the sulfonation reaction time is 2~6h.

[0014] Further, in step S4, the volume ratio of dimethyl sulfoxide to water is (9~99):1, the temperature of solvation is 4~20℃, and the time of solvation is 2~6h.

[0015] Furthermore, in step S8, the homogenization emulsification temperature is 75~78℃, and the vacuum degree is -0.10~-0.06MPa.

[0016] Furthermore, in step S9, the temperature at which triethanolamine is added is 40~50°C.

[0017] Furthermore, in step S10, the temperature at which O-sulfonated carboxymethyl chitosan is added is 35~40℃.

[0018] Furthermore, in step S11, the temperature at which the recombinant collagen aqueous solution is added is 30~35℃.

[0019] In steps S8 to S11 above, the emulsification temperature (75~78℃), neutralization temperature (40~50℃), intermediate dispersion temperature (35~40℃), and collagen addition temperature (30~35℃) form a decreasing temperature gradient: first, high-temperature emulsification ensures the full formation of the cream matrix, and then the temperature is gradually reduced to protect the heat-sensitive active components; O-sulfonated carboxymethyl chitosan is added before recombinant collagen, and the sulfonic acid groups and carboxyl groups on its molecular chain form ion pairing with the amino groups of lysine residues in collagen to construct a polyelectrolyte composite sustained-release network, which forms a sustained-release flexible protective film after the dressing is formed.

[0020] Thirdly, the present invention provides the application of the above-mentioned recombinant collagen-based ointment-type biological dressing for wound repair in the preparation of medical dressings that promote wound healing.

[0021] Compared with the prior art, the beneficial effects achieved by the present invention are: (1) The sulfonic acid array of the O-sulfonated carboxymethyl chitosan of the present invention mimics the glycosaminoglycan structure of heparan sulfate, and captures and stabilizes endogenous FGF-2 and VEGF in the patient's own exudate in situ at the wound site: it has specific binding ability to both FGF-2 and VEGF165, and the half-life of bound FGF-2 and VEGF165 under trypsin challenge is extended from less than 1 hour in the free state to 4-10 hours and 4-8 hours, respectively, which can significantly promote wound healing without the need for exogenous growth factors; animal experiments show that the dressing of the present invention achieves a wound healing rate of 90% 3-4 days earlier than the dressing of unsulfonated carboxymethyl chitosan.

[0022] (2) This invention introduces sulfonic acid groups through sulfonation reaction and then removes N-sulfate byproducts through selective solvent removal in aqueous dimethyl sulfoxide, thereby decoupling the growth factor binding function from the anticoagulant side effects: the anticoagulant activity is much lower than that of heparin, avoiding the risk of sulfonated polysaccharides interfering with the body's coagulation function after being absorbed by the wound; at the same time, the retention of free amino groups allows the material to maintain its antibacterial and film-forming properties, overcoming the functional defects of the high-strength sulfonation route.

[0023] (3) The preparation method of the present invention adopts a decreasing temperature gradient emulsification process: emulsification at 75~78℃, neutralization and thickening at 40~50℃, addition of O-sulfonated carboxymethyl chitosan at 35~40℃, and addition of recombinant collagen at 30~35℃. This avoids irreversible aggregation and inactivation of collagen at high emulsification temperature. The retention rate of the triple helix structure of recombinant collagen in the finished product is maintained at more than 90%, which is significantly higher than 55%~65% when added in the range of 40~50℃. O-sulfonated carboxymethyl chitosan is added before collagen and fully interpenetrates with carbomer and xanthan gum in the aqueous phase. It forms a polyelectrolyte composite sustained-release network with collagen through ion pairing. After the dressing is formed, it is a sustained-release flexible protective film. The film-forming performance, viscosity, pH value and other indicators all meet the requirements of medical dressing registration test. Attached Figure Description

[0024] Figure 1 This is a flowchart illustrating the preparation process of the recombinant collagen-based ointment-type biological dressing for wound repair according to the present invention.

[0025] Figure 2 This is a curve showing the full-thickness wound healing rate of rats in Example 1 of the present invention and in each control group. Detailed Implementation

[0026] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0027] The recombinant type III collagen in this embodiment of the invention uses a recombinant type III collagen sponge product (such as product model YHCOL002-II). The quality of the product meets the product technical requirements formulated according to YY / T 1849-2022 "Recombinant Collagen". The actual test results of specific batches of products are as follows: pH value 5.9, isoelectric point 5.86, protein content 87%, purity 96%, moisture content 6%, bacterial endotoxin less than 0.5 EU / mg, and exogenous DNA residue 0.03 ng / mg.

[0028] The carboxymethyl chitosan used in this embodiment of the invention is a medical-grade raw material with the following specifications: viscosity-average molecular weight of 80,000 to 150,000 Da (the measured viscosity-average molecular weight of the batch used in this embodiment of the invention is 105,000 Da), degree of deacetylation ≥90% (measured 92.3%), degree of carboxymethyl substitution of 0.75 to 0.90 (measured 0.82, of which the proportion of O-position carboxymethyl substitution accounts for ≥85% of the total substitution), purity ≥95% (measured 97.8% on a dry basis), moisture ≤8%, ash content ≤1%, and heavy metals ≤10 μg / g. The above molecular weight, degree of deacetylation, and degree of carboxymethyl substitution together determine the number of sulfonable sites (C3-hydroxyl, C6-hydroxyl, and free amino groups) on each sugar unit; the molar ratio of sugar units to sulfur trioxide pyridine complex in step S2 is calculated based on the molar amount of sugar units (calculated from the sample weight, measured viscosity-average molecular weight, and degree of substitution) to ensure process reproducibility. The sulfur trioxide pyridine complex has a purity of ≥98%, and both N,N-dimethylformamide and dimethyl sulfoxide are pharmaceutical grade.

[0029] Example 1 like Figure 1 As shown, this embodiment provides a recombinant collagen-based ointment-type biological dressing for wound repair, the preparation method of which includes the following steps: S1 Low-temperature swelling: Weigh 10g of carboxymethyl chitosan and disperse it in 500mL of N,N-dimethylformamide. Swell at 7℃ for 12h to allow the solvent to fully penetrate into the molecular chain. S2 sulfonation: The temperature was raised to 32.5℃, and sulfur trioxide pyridine complex was added in 3 batches. The molar ratio of carboxymethyl chitosan sugar units to sulfur trioxide pyridine complex was controlled to be 1:2.25. The mixture was stirred at 32.5℃ for 4 hours to obtain N,O- mixed sulfonated products. S3 alcohol precipitation purification: Pour the reaction solution into 4 times the volume of anhydrous ethanol, centrifuge to collect the precipitate, redissolve the precipitate in purified water to remove N,N-dimethylformamide and pyridine. S4 de-sulfonation: The complex solution obtained from S3 is mixed with dimethyl sulfoxide, and the volume ratio of dimethyl sulfoxide to water is controlled at 19:1. The mixture is stirred and solvated at 15°C for 4 hours to selectively remove the N-sulfate ester generated by the side reaction. S5 Dialysis Desalination and Freeze-drying: The feed solution was transferred to a dialysis bag with a molecular weight cutoff of 3.5 kDa and dialyzed for 72 hours, with water changed 7 times, until the conductivity of the dialysate was less than 10 μS / cm; the pH of the feed solution was adjusted to 6.5 with 0.1 mol / L sodium hydroxide aqueous solution to convert the sulfonic acid group to the sodium form; then it was pre-frozen at -50℃ for 4 hours and freeze-dried under vacuum at 15 Pa for 48 hours to obtain a white fibrous solid, namely the sodium form O-sulfonated carboxymethyl chitosan intermediate, whose 1% aqueous solution has a pH of 6.8; The structure of the O-sulfonated carboxymethyl chitosan intermediate obtained in this embodiment was characterized as follows: Ion chromatography was used to determine the acid-labile sulfate groups and total sulfate groups, calculating the O-sulfonation degree to be 1.30–1.40 (per sugar unit), and the N-sulfonation degree to be less than 0.05. The removal rate of N-sulfate esters by S4 solvation was greater than 90%, while the O-sulfonation degree was essentially unaffected. The ninhydrin colorimetric method showed a free amino content of 3.6–4.0 mmol / g, reaching more than 85% of the unsulfonated carboxymethyl chitosan control (4.2–4.5 mmol / g), and the ninhydrin reaction of the intermediate was purple, indicating that the free amino groups were retained. The pH of the intermediate aqueous solution (1%, w / v) was 6.8, and the sulfonic acid group was sodium-form, matching the pH of the carbomer system after triethanolamine neutralization, thus not disturbing the thickening state of the dressing matrix when S10 was added.

[0030] S6 Aqueous Phase Preparation: Add purified water and glycerol to an emulsifying pot, add carbomer pre-swollen with purified water, then add xanthan gum, disodium edetate, methylparaben and propylparaben, heat to 75°C and stir until homogeneous; S7 oil phase preparation: Cetearyl alcohol, liquid paraffin, dimethyl silicone oil and polysorbate 80 are put into the oil phase pot, electrically heated to melt, and the temperature is raised to 78°C; S8 Vacuum Homogenization Emulsification: The oil phase is vacuum-introduced into the emulsification pot under a vacuum of -0.08MPa and homogenized at 3000r / min for 15min at 76.5℃. S9 neutralization and thickening: Cool the jacket to 45°C, add triethanolamine, and stir for 10 minutes; S10 intermediate dispersion: Continue cooling to 37.5℃, add O-sulfonated carboxymethyl chitosan intermediate pre-dissolved in 10 times its weight of purified water, and disperse by stirring at 80 r / min for 30 min with a frame-type stirrer; after dispersion, samples were taken at the top, middle and bottom of the emulsification pot, and the contents of O-sulfonated carboxymethyl chitosan were determined by ion chromatography to be 1.28 wt%, 1.23 wt%, and 1.25 wt% (relative standard deviation of 2.0%), indicating uniform dispersion; S11 Collagen Addition, Defoaming and Filling: Continue cooling to 32.5℃, add the recombinant collagen aqueous solution prepared in purified water, and stir at a low speed of 50r / min for 20min until uniform; then maintain stirring at a slow speed of 20r / min, vacuum to -0.09MPa, and defoam for 12min to obtain the recombinant collagen-based ointment-type biological dressing for wound repair.

[0031] The composition of the dressing in this embodiment is as follows: O-sulfonated carboxymethyl chitosan 1.25wt%, recombinant collagen 0.6wt%, cetearyl alcohol 6wt%, liquid paraffin 8wt%, dimethicone 4wt%, polysorbate 80 2.5wt%, glycerin 8wt%, carbomer 0.4wt%, xanthan gum 0.2wt%, triethanolamine 0.6wt%, methylparaben 0.15wt%, propylparaben 0.06wt%, disodium edetate 0.045wt%, and the balance is purified water 68.195wt%.

[0032] Example 2 like Figure 1As shown, this embodiment provides a recombinant collagen-based ointment-type biological dressing for wound repair, which differs from Example 1 in the following ways: In step S1, the low-temperature swelling temperature is 4°C and the swelling time is 10h; in step S2, the molar ratio of carboxymethyl chitosan units to sulfur trioxide pyridine complex is 1:1.5, the sulfonation reaction temperature is 20°C, and the sulfonation reaction time is 2h; in step S4, the volume ratio of dimethyl sulfoxide to water is 9:1, the solvation temperature is 4°C, and the solvation time is 2h; in step S5, the water is changed 6 times by dialysis, and the pressure of vacuum freeze-drying is 10Pa; in step S8, the homogenization emulsification temperature is 75°C, and the vacuum degree is -0.10MPa; in step S9, the temperature for adding triethanolamine is 40°C; in step S10, the temperature for adding O-sulfonated carboxymethyl chitosan is 35°C; in step S11, the temperature for adding recombinant collagen aqueous solution is 30°C, and the remaining steps are the same as in Example 1. The dressing contains the following components: 0.5 wt% O-sulfonated carboxymethyl chitosan, 0.2 wt% recombinant collagen, 5 wt% cetearyl alcohol, 7 wt% liquid paraffin, 3 wt% dimethicone, 2 wt% polysorbate 80, 7 wt% glycerin, 0.3 wt% carbomer, 0.1 wt% xanthan gum, 0.4 wt% triethanolamine, 0.1 wt% methylparaben, 0.04 wt% propylparaben, 0.03 wt% disodium edetate, and the balance being 74.33 wt% purified water.

[0033] Example 3 like Figure 1As shown, this embodiment provides a recombinant collagen-based ointment-type biological dressing for wound repair, which differs from Example 1 in the following ways: In step S1, the low-temperature swelling temperature is 10°C and the swelling time is 14h; in step S2, the molar ratio of carboxymethyl chitosan sugar units to sulfur trioxide pyridine complex is 1:3.0, the sulfonation reaction temperature is 45°C, and the sulfonation reaction time is 6h; in step S4, the volume ratio of dimethyl sulfoxide to water is 99:1, the solvation temperature is 20°C, and the solvation time is 6h; in step S5, the water is changed 8 times by dialysis, and the pressure of vacuum freeze-drying is 20Pa; in step S8, the homogenization emulsification temperature is 78°C, and the vacuum degree is -0.06MPa; in step S9, the temperature at which triethanolamine is added is 50°C; in step S10, the temperature at which O-sulfonated carboxymethyl chitosan is added is 40°C; in step S11, the temperature at which the recombinant collagen aqueous solution is added is 35°C, and the remaining steps are the same as in Example 1. The dressing contains the following components: O-sulfonated carboxymethyl chitosan 2.0 wt%, recombinant collagen 1.0 wt%, cetearyl alcohol 7 wt%, liquid paraffin 9 wt%, dimethicone 5 wt%, polysorbate 80 3 wt%, glycerin 9 wt%, carbomer 0.5 wt%, xanthan gum 0.3 wt%, triethanolamine 0.8 wt%, methylparaben 0.2 wt%, propylparaben 0.08 wt%, disodium edetate 0.06 wt%, and the balance is purified water 62.06 wt%.

[0034] Comparative Example 1 This comparative example provides a recombinant collagen-based ointment-type biological dressing for wound repair. The only difference from Example 1 is that in dressing preparation step S10, an equal mass of unsulfonated carboxymethyl chitosan is used to directly replace the O-sulfonated carboxymethyl chitosan intermediate. It is pre-dissolved in 10 times its mass of purified water in the same manner and then added. That is, the raw material carboxymethyl chitosan used in Example 1 is not processed by the intermediate preparation step. The remaining components, dosages and preparation steps are the same as in Example 1.

[0035] Comparative Example 2 This comparative example provides a recombinant collagen-based ointment-type biological dressing for wound repair. The only difference from Example 1 is that in dressing preparation step S10, an equal mass of sodium heparin is used to replace the O-sulfonated carboxymethyl chitosan intermediate, and it is added after being prepared into an aqueous solution in the same manner. The remaining components, dosages, and preparation steps are the same as in Example 1.

[0036] Comparative Example 3 This comparative example provides a recombinant collagen-based ointment-type biological dressing for wound repair. The only difference between its preparation and that of Example 1 is the omission of step S4. That is, the reconstituted solution obtained in S3 is directly dialyzed to remove salt and freeze-dried (the remaining steps are the same as in Example 1) to obtain a mixed N,O-sulfonated product with N-sulfonate groups not removed, which is designated as the intermediate of Comparative Example 3. This intermediate is used to investigate the effect of step S4 (solvent-de-N-sulfonation). The degree of O-sulfonation of the intermediate of Comparative Example 3 is 1.30~1.35, and the degree of N-sulfonation is 0.40~0.50 (based on per sugar unit).

[0037] The finished product testing was conducted according to the approved testing plan: pH value: Take 10g of this product, add 90mL of freshly boiled and cooled purified water, stir continuously until completely dissolved, and determine according to General Chapter 0631 of Part IV of the 2025 edition of the Chinese Pharmacopoeia; Viscosity: Take 100g of this product, equilibrate in a water bath at 25℃ for 30min, and determine using a rotational viscometer according to Method III of General Chapter 0633; Film-forming properties: Take an appropriate amount of this product, spread it evenly on a petri dish with a diameter of 9cm, dry at 37℃, and observe; Microbial limits were tested according to the microbial limit test method. The integrity of the triple helix structure of recombinant collagen was determined by circular dichroism spectroscopy (scanning in the far ultraviolet region 190~260nm, characterized by the ratio of the absolute values ​​of the 221nm positive peak to the 198nm negative peak, Rpn); Identification of O-sulfonated carboxymethyl chitosan was performed by attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR), with a blank matrix without O-sulfonated carboxymethyl chitosan and with the same other components as a negative control. The test results are shown in Table 1.

[0038] Table 1. Finished Product Inspection Results of Example 1

[0039] The finished products of Examples 2 and 3 were tested according to the same testing methods corresponding to their respective formulation specifications. Appearance, fill weight, pH value, viscosity, identification, content, heavy metals, film-forming properties, triple helix structure integrity, and microbial limits all met the requirements. Specifically, Example 2 had a pH value of 6.8–6.9, a viscosity of 3800–4500 mPa·s, a recombinant collagen content of 2.0–2.2 mg / mL, and a triple helix structure integrity Rpn of 0.11–0.12; Example 3 had a pH value of 7.0–7.1, a viscosity of 5500–6500 mPa·s, a recombinant collagen content of 9.6–10.8 mg / mL, and a triple helix structure integrity Rpn of 0.11–0.13.

[0040] Collagen Addition Temperature Sensitivity Test: To investigate the effect of collagen addition temperature in step S11 on the structural integrity of recombinant collagen in the finished product, the same batch of material from Example 1 was used, and recombinant collagen aqueous solution was added at 32.5℃ (within the range of 30~35℃ limited by this invention) and 45℃ (40~50℃, exceeding the range limited by this invention), respectively. All other steps were the same as in Example 1, resulting in two finished products. The far-ultraviolet CD spectrum of recombinant collagen in the finished product was determined by circular dichroism spectroscopy. The triple helix structure content of freshly prepared recombinant collagen aqueous solution from the same batch was used as a 100% control, and the triple helix structure retention rate in the finished product was calculated. Results: The triple helix structure retention rate of the product added at 32.5℃ was 90%~95%, while that added at 45℃ was 55%~65%. This indicates that controlling the collagen addition temperature within the range of 30~35℃ can effectively maintain the integrity of the triple helix structure of recombinant collagen, verifying the necessity of this temperature limitation in the decreasing temperature gradient emulsification process.

[0041] The binding capacity and affinity of FGF-2 and VEGF165 were determined using surface plasmon resonance (SPR). Recombinant human FGF-2 and recombinant human VEGF165 were coupled to the surfaces of two-channel sensor chips, respectively. A series of aqueous solutions were prepared from the O-sulfonated carboxymethyl chitosan intermediates obtained in Examples 1-3, the unsulfonated carboxymethyl chitosan used in Comparative Example 1, the heparin sodium used in Comparative Example 2, and the intermediate obtained in Comparative Example 3 (a product sulfonated only by S1-S3, without N-sulfonation by solvent desorption in S4). These solutions were then passed through the chip surface. The binding capacity per unit mass and the equilibrium dissociation constant K were calculated from the binding response values. D The experimental results are shown in Table 2.

[0042] Trypsin challenge assay: FGF-2 or VEGF165 was co-incubated with each sample in phosphate buffer (FGF-2 or VEGF165 final concentration 20 μg / mL, sample final concentration 1 mg / mL). 0.05% trypsin was added, and the reaction was carried out in a 37℃ water bath. Samples were taken at different time points, and the immunoreactivity of residual FGF-2 or VEGF165 was determined by enzyme-linked immunosorbent assay (ELISA), and the half-life was calculated. Free FGF-2 and free VEGF165 controls (without sample) were also included. The experimental results are shown in Table 2.

[0043] Table 2. Binding and stabilizing effects of each sample on FGF-2 and VEGF165.

[0044] As shown in Table 2, the O-sulfonated carboxymethyl chitosan intermediates of Examples 1-3 exhibit specific binding ability to both FGF-2 and VEGF165. DThe concentration reached the μmol / L level; the trypsin challenge half-life of bound FGF-2 and VEGF165 was extended from less than 1 h in the free state to 4-10 h and 4-8 h, respectively, an extension of more than 4 times. Unsulfonated carboxymethyl chitosan (Comparative Example 1) hardly bound FGF-2 and VEGF165, with a half-life comparable to the free state, indicating that the sulfonic acid array is a necessary structural basis for capturing endogenous growth factors. The binding ability of the intermediate in Comparative Example 3 (without S4 solvation) to FGF-2 and VEGF165 was comparable to that in Example 1, indicating that the presence or absence of N-sulfate groups has little effect on growth factor binding function; the difference in the effect of S4 is reflected in anticoagulant activity, free amino group retention, and antibacterial properties (see Tables 3 and 6). The binding ability of heparin sodium (Comparative Example 2) was comparable to that in Example 1, indicating that the O-sulfonated carboxymethyl chitosan of the present invention achieves a growth factor presentation function comparable to heparin.

[0045] Anticoagulant activity assay: The activated partial thromboplastin time (APTT) method was used. Rabbit plasma anticoagulated with sodium citrate was used as the substrate. A series of concentrations of the test sample aqueous solution were added, followed by recalcification with calcium chloride solution. The plasma coagulation time was recorded. A standard curve was prepared using heparin sodium standard, and the coagulation time of each sample was converted to anticoagulant activity (IU / mg). The test samples were: intermediates from Examples 1-3, the intermediate obtained from Comparative Example 3 (the product sulfonated only by S1-S3, without solvent desorption of N-sulfonation in S4), heparin sodium from Comparative Example 2, and an over-sulfonated reference sample—this reference sample was prepared by increasing the molar ratio of carboxymethyl chitosan units to the sulfur trioxide pyridine complex to 1:4.5 (exceeding the 1:1.5-1:3.0 range limited by this invention), with the remaining operations being the same as the intermediate preparation steps (S1 to S5) of Example 1. The experimental results are shown in Table 3.

[0046] Table 3 Results of anticoagulant activity assay for each sample

[0047] As shown in Table 3, the anticoagulant activity of the intermediates in Examples 1-3 was significantly lower than that of heparin sodium (>150 IU / mg), achieving decoupling of growth factor binding function and anticoagulant side effects, thus meeting the biosafety requirements for topical dressings. When the molar ratio of the sulfonating reagent exceeded the upper limit specified in this invention, the anticoagulant activity of the over-sulfonated reference sample increased to 35-40 IU / mg, which no longer met the safety requirements for topical dressings. This indicates that the sulfonation process parameter range specified in this invention (molar ratio 1:1.5-1:3.0, 20-45℃, 2-6h) is a necessary guarantee for balancing the sulfonic acid array function and the N-amino retained phase. The intermediate of Comparative Example 3, which was not solvated by S4, showed an anticoagulant activity of 20-30 IU / mg due to residual N-sulfate groups, significantly higher than that of the intermediates in Examples 1-3. This indicates that selective solvation by S4 is a key step in achieving decoupling of growth factor binding function and anticoagulant side effects. The antibacterial performance of each sample is investigated in the antibacterial performance test below and Table 6.

[0048] Full-thickness skin defect healing experiment in rats: Twenty-four SPF-grade SD rats, half male and half female, weighing 200-250g, were randomly divided into four groups of six rats each: the dressing group of Example 1, the dressing group of Comparative Example 1, the blank matrix group (the dressing contained 0.6wt% recombinant collagen as in Example 1, without O-sulfonated carboxymethyl chitosan, and replaced with an equal amount of purified water; the remaining components were the same as in Example 1), and the blank control group (the wound was covered only with sterile medical gauze). After anesthesia with sodium pentobarbital, the back was prepared and disinfected, and a full-thickness skin defect with a diameter of 1.5cm was prepared on the back of each rat. The dressings in each group were changed once a day for 21 consecutive days. Wound area was measured using imaging on days 3, 7, 10, 14, 17, and 21. The wound healing rate was calculated using the formula: "Healing rate = (Initial wound area - Wound area on the current day) / Initial wound area × 100%". On day 10, wound edge tissue was taken for CD31 immunohistochemical staining to count microvessel density. On day 21, wound tissue was taken for Masson's trichrome staining, and collagen deposition area fraction was determined using image analysis. The t-test was used for comparisons between groups, with P < 0.05 considered statistically significant. Animal experiments followed the guidelines for the use and management of laboratory animals. Wound healing rates for each group are shown in Table 4, histological examination results are shown in Table 5, and wound healing rate curves for each group are shown in [Table 5]. Figure 2 .

[0049] Table 4. Wound healing rate (%) in each group of rats

[0050] Table 5. Histological examination results of wounds in each group

[0051] In Example 1, the healing rate of the dressing group reached over 90% (91.5% ± 1.8%) by day 14, which was 3-4 days earlier than that of the control group (90% by day 17-18), about 6 days earlier than that of the blank matrix group (90% by day 20-21), and about 7 days earlier than that of the blank control group (90% by day 21). Compared with the control group, the differences at each time point were statistically significant (P < 0.05), and compared with the blank matrix group and the blank control group, the differences at each time point were also statistically significant (P < 0.01). The healing rate of the blank matrix group was higher than that of the blank control group from day 7 to day 17 (P < 0.05), indicating that recombinant collagen itself has a certain promoting effect on wound healing. The addition of O-sulfonated carboxymethyl chitosan to the blank matrix significantly improved the healing speed, indicating that in-situ capture of endogenous growth factors is the main contributing factor to accelerated wound healing. In Example 1, the microvascular density on day 10 and the collagen deposition area fraction on day 21 were significantly higher than those in the control group, blank matrix group, and blank control group (P<0.01). This indicates that O-sulfonated carboxymethyl chitosan effectively promotes granulation tissue vascularization and extracellular matrix collagen deposition by capturing and stabilizing endogenous growth factors in wound exudate in situ. This in vivo experimental verification verifies the mechanism of transforming the "present but ineffective" endogenous growth factors in wounds into "present and highly effective" endogenous growth factors.

[0052] Antibacterial performance test: Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 6538) were used as test bacteria. The shaking flask method was adopted: each sample was prepared into a 1 mg / mL aqueous solution, and 5 mL and 0.1 mL of the solution were taken to obtain a bacterial count of approximately 1 × 10⁻⁶. 6 The test bacterial suspension was mixed with CFU / mL and cultured at 37℃ and 150 rpm for 24 h with shaking. Samples were then taken, serially diluted 10-fold with phosphate buffer, and poured onto plates for viable bacterial count. Purified water was used as a control instead of the sample solution. The inhibition rate was calculated as (control group colony count - sample group colony count) / control group colony count × 100%, with three replicates per group. The test samples were the intermediates of Examples 1-3, the intermediate obtained in Comparative Example 3, and unsulfonated carboxymethyl chitosan (the raw material used in Comparative Example 1). The experimental results are shown in Table 6.

[0053] Table 6. Antibacterial rate (%) of each sample

[0054] As shown in Table 6, the intermediates of Examples 1-3 maintained an inhibition rate of over 60% against Escherichia coli and Staphylococcus aureus, indicating that O-sulfonation modification only partially consumed the free amino group, and the antibacterial performance was not lost due to the introduction of sulfonic acid groups. The intermediate of Comparative Example 3, which was not solvated by S4, had an inhibition rate of less than 20% against both test bacteria because the free amino group was occupied by N-sulfate groups, which was significantly lower than that of Examples 1-3. This further proves the necessity of selective solvation by S4 for preserving the free amino group and antibacterial performance. The unsulfonated carboxymethyl chitosan had the highest inhibition rate, which is consistent with the highest free amino group density.

[0055] Finally, it should be noted that the above descriptions are merely preferred embodiments of the present invention and are not intended to limit the present invention. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent substitutions for some of the technical features. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A recombinant collagen-based ointment-type biological dressing for wound repair, characterized in that, The biological dressing is an ointment-type biological dressing made of active ingredients, excipient matrix and purified water; the active ingredients include O-sulfonated carboxymethyl chitosan and recombinant collagen. The O-sulfonated carboxymethyl chitosan is prepared by sulfonation of carboxymethyl chitosan and a sulfur trioxide pyridine complex.

2. The recombinant collagen-based ointment-type biological dressing for wound repair according to claim 1, characterized in that, The biological dressing contains 0.5-2.0 wt% O-sulfonated carboxymethyl chitosan and 0.2-1.0 wt% recombinant collagen, with the remainder being excipient matrix and purified water.

3. The recombinant collagen-based ointment-type biological dressing for wound repair according to claim 1, characterized in that, The excipient matrix comprises, by weight percentage: 5-7 wt% cetearyl alcohol, 7-9 wt% liquid paraffin, 3-5 wt% dimethicone, 2-3 wt% polysorbate 80, 7-9 wt% glycerin, 0.3-0.5 wt% carbomer, 0.1-0.3 wt% xanthan gum, 0.4-0.8 wt% triethanolamine, 0.1-0.2 wt% methylparaben, 0.04-0.08 wt% propylparaben, and 0.03-0.06 wt% disodium edetate.

4. A method for preparing a recombinant collagen-based ointment-type biological dressing for wound repair as described in any one of claims 1 to 3, characterized in that, Includes the following steps: S1. Disperse carboxymethyl chitosan in N,N-dimethylformamide and allow it to swell; S2. Add sulfur trioxide pyridine complex in batches to carry out sulfonation reaction; S3. Pour the reaction solution into anhydrous ethanol for alcohol precipitation, centrifuge to collect the precipitate, and redissolve the precipitate in purified water to obtain a redissolved solution. S4. Solvation of the complex solution in aqueous dimethyl sulfoxide to selectively remove N-sulfate; S5. Dialysis to remove salt, converting the sulfonic acid group to the sodium form, freeze drying to obtain O-sulfonated carboxymethyl chitosan intermediate; S6. Mix purified water, glycerol, pre-swollen carbomer, xanthan gum, disodium edetate, methylparaben, and propylparaben, heat and stir to dissolve, and obtain an aqueous phase; S7. Mix and melt cetearyl alcohol, liquid paraffin, dimethyl silicone oil and polysorbate 80 to obtain the oil phase; S8. Vacuum draw the oil phase into the emulsification pot and homogenize and emulsify it under vacuum conditions. S9. Cool down, add triethanolamine and stir to neutralize and thicken; S10. Continue cooling, add O-sulfonated carboxymethyl chitosan pre-dissolved in purified water, and stir to disperse; S11. Continue cooling, add recombinant collagen aqueous solution, stir evenly, and degas under vacuum to obtain the recombinant collagen-based ointment-type biological dressing for wound repair.

5. The preparation method according to claim 4, characterized in that, In S1, the swelling temperature is 4~10℃.

6. The preparation method according to claim 4, characterized in that, In S2, the molar ratio of the sugar units of carboxymethyl chitosan to the sulfur trioxide pyridine complex is 1:(1.5~3.0); the sulfonation reaction temperature is 20~45℃, and the sulfonation reaction time is 2~6h.

7. The preparation method according to claim 4, characterized in that, In S4, the volume ratio of dimethyl sulfoxide to water is (9~99):1, the solvation temperature is 4~20℃, and the solvation time is 2~6h.

8. The preparation method according to claim 4, characterized in that, In S8, the homogenization emulsification temperature is 75~78℃, and the vacuum degree is -0.10~-0.06MPa.

9. The preparation method according to claim 4, characterized in that, In S9, triethanolamine is added at a temperature of 40~50℃.

10. The preparation method according to claim 4, characterized in that, In S10, the temperature at which O-sulfonated carboxymethyl chitosan is added is 35~40℃.

11. The preparation method according to claim 4, characterized in that, In S11, the temperature at which the recombinant collagen aqueous solution is added is 30~35℃.

12. The use of a recombinant collagen-based ointment-type biological dressing for wound repair as described in any one of claims 1 to 3 in the preparation of a medical dressing that promotes wound healing.

Citation Information

Patent Citations

  • A method for synthesizing a sulfated product of 6-O-carboxymethyl chitosan

    CN104231112B

  • Transdermal absorption repairing cream and preparation method thereof

    CN121313520A